Strata Critical Medical, Inc. (SRTA) Stock

Understand Strata Critical Medical, Inc.: how it makes money

Strata Critical Medical airlifts and ground-transports human organs to transplant centers and runs organ-recovery hubs, billing hospitals per shipment and per clinical case. The business splits roughly evenly between logistics and clinical services, and no single customer is dominant enough to anchor pricing.

The 35-aircraft fleet spread across 20 air bases means each additional organ run adds almost no cost, but if utilization drops below a critical threshold the 21% gross margin cannot absorb fixed overhead and operations turn negative.

Business quality (Weak): Weak: 2% revenue growth, negative operating margin (-7.5%), and a 48% valuation discount to the sector all point to an unproven model that has not yet reached profitable scale.

Valuation: At 13× earnings, SRTA trades 48% below the Healthcare Services average (25×). Note: the low multiple may reflect one-time earnings items.

Bull case

• Clinical segment accelerating: Management guides clinical revenue to grow approximately 20% sequentially in Q3, signaling the organic growth engine is compounding on top of the acquisition base.
• M&A unlocking EBITDA: Three recent acquisitions added more than $20 million in revenue and $6.3 million in projected annualized adjusted EBITDA, giving the P&L a clear path toward positive operating leverage by late 2026.
• Valuation far below sector: The stock trades at a P/E of 13.3x versus the Healthcare Services industry average of 25x, a 48% discount that leaves substantial re-rating room if clinical growth persists through the year.

Bear case

• Logistics volume eroding: Management expects logistics revenue to decline high single digits sequentially in Q3, weakening the segment that already represents 50% of total revenue and funds the fixed network.
• Margin target receding: Logistics margin is guided to stay below the 20% internal target through all of 2026, capping earnings upside even if the revenue line stabilizes next quarter.
• Transplant demand softening: Several transplant centers accepted fewer organs for transplant from July onward, a leading indicator that run volume could dip further before any recovery in organ availability.

Related Companies (Healthcare Services; 8 comparable companies)

• Talkspace, Inc. (TALK)
• Omada Health (OMDA)
• GeneDx Holdings Corp. (WGS)
• U.S. Physical Therapy, Inc. (USPH)
• InnovAge Holding Corp. (INNV)
• The Pennant Group, Inc. (PNTG)
• LifeStance Health Group, Inc. (LFST)
• P3 Health Partners Inc. (PIII)